Press Releases

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences

Feb 22 2018

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, today announced that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018. IO360… Read more »

Intensity Therapeutics Issued New Patents for Technology Platform

Jun 22 2017

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338. “Intensity’s DfuseRxSM platform has identified our lead drug, INT230-6. This… Read more »

Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial

May 22 2017

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the US Food and… Read more »

View All Press Releases